Dezawa MuseCells® continue to draw attention across a wide range of medical disciplines, from neurology to cardiology to orthopedics. This breadth is unusual for a single cell type and reflects a specific biological property: Muse cells are naturally occurring, pluripotent-like stem cells that selectively travel to damaged tissue throughout the body. Because this mechanism is not organ-specific, researchers in multiple specialties have independently begun investigating how Muse cells behave in their respective fields. This article reviews where that research currently stands and why it is important to separate ongoing scientific investigation from established, approved treatment.
What Makes Muse Cells Relevant to So Many Specialties
First identified in 2010 by Professor Mari Dezawa and colleagues at Tohoku University, Muse cells are defined by the surface marker SSEA-3 and are found naturally in bone marrow, adipose tissue, peripheral blood, and connective tissue throughout the body. Unlike induced pluripotent stem cells (iPSCs) or embryonic stem cells, Muse cells require no genetic reprogramming and have not been shown to form tumors in laboratory models. Their defining trait is a homing mechanism: Muse cells detect sphingosine-1-phosphate (S1P), a lipid signal released by damaged tissue, through a receptor called S1PR2. This allows circulating Muse cells to migrate toward an injury site regardless of which organ system is affected, which is the underlying reason investigators across specialties have taken interest in the cell type.
Current Areas of Scientific Investigation
Neurologic Research
In neurology, Muse cells have been studied in the context of ischemic stroke, spinal cord injury, amyotrophic lateral sclerosis (ALS), and neonatal hypoxic-ischemic encephalopathy. Preclinical work has shown that intravenously administered Muse cells can home to the spinal cord and brain and differentiate into neuronal and glial-lineage cells. Early-phase clinical trials conducted in Japan have evaluated safety and tolerability of a Muse cell-based product in these populations, with functional outcome measures tracked over periods of several months to a year.
Cardiovascular Research
Cardiology research has focused primarily on acute myocardial infarction (AMI). Animal studies have demonstrated that Muse cells delivered intravenously after a heart attack migrate preferentially to infarcted tissue, differentiate into cardiomyocyte- and vascular-lineage cells, and are associated with reduced infarct size and improved left ventricular function in these models. Clinical investigation in AMI patients has examined whether circulating Muse cell counts correlate with recovery of heart function after infarction.
Orthopedic and Musculoskeletal Research
In orthopedics, investigators are examining how Muse cells might contribute to joint tissue and cartilage repair, building on the cell’s general tissue-homing and differentiation properties. This area remains earlier-stage compared to cardiovascular or neurologic research, with most current work limited to preclinical models.
Pulmonary Research
Pulmonary investigation has included work related to acute respiratory distress conditions, where researchers have studied whether Muse cells’ immunomodulatory properties, including expression of HLA-G, may influence inflammatory lung injury. This area is still primarily preclinical and early clinical in scope.
Tissue Regeneration Research More Broadly
Beyond organ-specific fields, Muse cells have also been studied in dermatology, specifically in dystrophic epidermolysis bullosa, a genetic skin condition causing chronic wounding. Trials in this population have tracked wound area and pain scores following intravenous Muse cell administration, contributing to the broader evidence base on how these cells behave once infused into human subjects.
Across these fields, several recurring research themes appear:
- Homing specificity – whether Muse cells reliably localize to the intended injury site in a given organ system
- Differentiation fidelity – whether cells that reach the injury site differentiate into functionally appropriate tissue types
- Dosing and administration frequency – single-dose versus repeated intravenous administration protocols
- Long-term safety – tumorigenicity, immune response, and persistence of engrafted cells over time
- Functional outcome measures – condition-specific scales, such as neurological function scores or cardiac ejection fraction
Distinguishing Research From Established Therapy
Because Muse cell research spans so many fields and includes completed clinical trials in some conditions, it is easy to conflate active investigation with established, approved treatment. These are not the same thing, and the distinction depends on where a given application sits in the research pipeline.
Preclinical and Translational Research
Most orthopedic and pulmonary applications remain at this stage: laboratory and animal studies designed to establish mechanism, dosing, and safety signals before any human testing begins.
Clinical Trial Phases
Conditions such as AMI, stroke, ALS, spinal cord injury, and epidermolysis bullosa have progressed into early-phase human trials, primarily in Japan, evaluating safety and preliminary efficacy signals. Phase 1 and Phase 2 trials are designed to answer safety and dosing questions first; they are not equivalent to the larger, controlled trials required for regulatory approval.
Regulatory Oversight
No Muse cell product currently holds full regulatory approval for routine clinical use in the United States. Any application discussed in the research literature should be understood as investigational unless a specific regulatory clearance is cited.
Why Multi-Field Interest Matters
The fact that neurology, cardiology, orthopedics, pulmonology, and dermatology researchers are independently studying the same cell type strengthens the overall evidence base for the underlying biological mechanism, even though each specialty is still working through its own condition-specific questions. Continued publication across these fields allows researchers to compare safety data, dosing approaches, and administration protocols across different patient populations, which is a normal and necessary part of how regenerative medicine research matures over time.
Frequently Asked Questions
Are Dezawa MuseCells® an approved treatment for any of these conditions?
No. Research described here spans preclinical studies and early-phase clinical trials. No Muse cell product currently holds full regulatory approval for routine use in these conditions in the United States.
Why do Muse cells appear relevant to so many different organ systems?
Their homing mechanism, driven by detection of the injury signal S1P through the S1PR2 receptor, is not organ-specific, which is why researchers in multiple fields have investigated the same cell type independently.
Which condition has the most clinical trial data so far?
Acute myocardial infarction and epidermolysis bullosa have some of the more established early-phase clinical trial histories, though sample sizes remain small relative to later-phase trials.
How is orthopedic research different from cardiovascular or neurologic research in this area?
Orthopedic applications remain largely at the preclinical stage, while cardiovascular and neurologic research has progressed further into early-phase human trials for specific conditions like AMI and stroke.
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.
